Advancements in the Management of Ovarian Cancer - Episode 7
Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs
Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.
Video content above is prompted by the following:
- Dr Chan to Dr Herzog: What adverse events are most seen with PARPi therapy, and how do you mitigate or manage these?
- Dr Herzog: Briefly comment on recent data surrounding ADCs in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
- Dr Herzog to address: Mirvetuximab soravtansine (anti-FR)
- FORWARD II (Gynecol Oncol. 2024 MIRASOL) (N Engl J Med. 2023; ASCO 2024 abstract 5582)
- Dr Chan to address: Luveltamab tazevibulin (anti-FR), Rinatabart sesutecan (Rina-S)
- Rinatabart sesutecan (Rina-S) - Lee EK, et al. ESMO 2024. Abs 719MO
- STRO-002-GM1 (Pothuri, et al. ESMO 2023. Abstract 741MO)
- All faculty: Please share future perspectives and closing thoughts on the treatment of ovarian cancer.
Related Content:
